nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—CYP1A2—Dacarbazine—pancreatic cancer	0.0977	0.232	CbGbCtD
Agomelatine—CYP1A2—Tamoxifen—pancreatic cancer	0.0777	0.185	CbGbCtD
Agomelatine—CYP2C9—Tamoxifen—pancreatic cancer	0.07	0.167	CbGbCtD
Agomelatine—CYP1A2—Erlotinib—pancreatic cancer	0.0661	0.157	CbGbCtD
Agomelatine—CYP1A2—Fluorouracil—pancreatic cancer	0.0573	0.136	CbGbCtD
Agomelatine—CYP2C9—Fluorouracil—pancreatic cancer	0.0516	0.123	CbGbCtD
Agomelatine—Indomethacin—CXCL8—pancreatic cancer	0.00271	0.32	CrCbGaD
Agomelatine—Nabumetone—PTGS2—pancreatic cancer	0.00211	0.249	CrCbGaD
Agomelatine—Indomethacin—PPARG—pancreatic cancer	0.00188	0.221	CrCbGaD
Agomelatine—Infestation—Fluorouracil—pancreatic cancer	0.00125	0.00484	CcSEcCtD
Agomelatine—Infestation NOS—Fluorouracil—pancreatic cancer	0.00125	0.00484	CcSEcCtD
Agomelatine—Mental disorder—Sunitinib—pancreatic cancer	0.00124	0.00483	CcSEcCtD
Agomelatine—Anxiety—Tamoxifen—pancreatic cancer	0.00122	0.00475	CcSEcCtD
Agomelatine—Anxiety—Erlotinib—pancreatic cancer	0.00121	0.0047	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00121	0.00469	CcSEcCtD
Agomelatine—Dry mouth—Tamoxifen—pancreatic cancer	0.0012	0.00466	CcSEcCtD
Agomelatine—Hepatobiliary disease—Gemcitabine—pancreatic cancer	0.0012	0.00466	CcSEcCtD
Agomelatine—Back pain—Sunitinib—pancreatic cancer	0.00119	0.00464	CcSEcCtD
Agomelatine—Infection—Tamoxifen—pancreatic cancer	0.00117	0.00454	CcSEcCtD
Agomelatine—Infection—Erlotinib—pancreatic cancer	0.00116	0.00449	CcSEcCtD
Agomelatine—Migraine—Docetaxel—pancreatic cancer	0.00115	0.00447	CcSEcCtD
Agomelatine—Connective tissue disorder—Irinotecan—pancreatic cancer	0.00115	0.00446	CcSEcCtD
Agomelatine—Nervous system disorder—Erlotinib—pancreatic cancer	0.00114	0.00444	CcSEcCtD
Agomelatine—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00114	0.00442	CcSEcCtD
Agomelatine—Skin disorder—Erlotinib—pancreatic cancer	0.00113	0.00439	CcSEcCtD
Agomelatine—Angioedema—Sunitinib—pancreatic cancer	0.00113	0.00438	CcSEcCtD
Agomelatine—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.00112	0.00435	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Epirubicin—pancreatic cancer	0.00108	0.00422	CcSEcCtD
Agomelatine—Abnormal dreams—Epirubicin—pancreatic cancer	0.00107	0.00417	CcSEcCtD
Agomelatine—Insomnia—Tamoxifen—pancreatic cancer	0.00106	0.00414	CcSEcCtD
Agomelatine—Paraesthesia—Tamoxifen—pancreatic cancer	0.00106	0.00411	CcSEcCtD
Agomelatine—Insomnia—Erlotinib—pancreatic cancer	0.00105	0.00409	CcSEcCtD
Agomelatine—Nasopharyngitis—Docetaxel—pancreatic cancer	0.00104	0.00406	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.00104	0.00406	CcSEcCtD
Agomelatine—Dyspepsia—Tamoxifen—pancreatic cancer	0.00104	0.00402	CcSEcCtD
Agomelatine—Dry mouth—Sunitinib—pancreatic cancer	0.00103	0.004	CcSEcCtD
Agomelatine—Dyspepsia—Erlotinib—pancreatic cancer	0.00102	0.00398	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00102	0.00395	CcSEcCtD
Agomelatine—Fatigue—Tamoxifen—pancreatic cancer	0.00101	0.00394	CcSEcCtD
Agomelatine—Constipation—Tamoxifen—pancreatic cancer	0.00101	0.00391	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.001	0.00391	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Doxorubicin—pancreatic cancer	0.001	0.0039	CcSEcCtD
Agomelatine—Fatigue—Erlotinib—pancreatic cancer	0.001	0.0039	CcSEcCtD
Agomelatine—Infection—Sunitinib—pancreatic cancer	0.001	0.00389	CcSEcCtD
Agomelatine—Constipation—Erlotinib—pancreatic cancer	0.000995	0.00387	CcSEcCtD
Agomelatine—Abnormal dreams—Doxorubicin—pancreatic cancer	0.000992	0.00385	CcSEcCtD
Agomelatine—Nervous system disorder—Sunitinib—pancreatic cancer	0.000988	0.00384	CcSEcCtD
Agomelatine—Back pain—Irinotecan—pancreatic cancer	0.000984	0.00382	CcSEcCtD
Agomelatine—Skin disorder—Sunitinib—pancreatic cancer	0.000979	0.0038	CcSEcCtD
Agomelatine—Naproxen—PTGS2—pancreatic cancer	0.000977	0.115	CrCbGaD
Agomelatine—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000962	0.00374	CcSEcCtD
Agomelatine—Back pain—Gemcitabine—pancreatic cancer	0.000958	0.00372	CcSEcCtD
Agomelatine—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000952	0.0037	CcSEcCtD
Agomelatine—Urticaria—Tamoxifen—pancreatic cancer	0.000935	0.00363	CcSEcCtD
Agomelatine—Abdominal pain—Tamoxifen—pancreatic cancer	0.00093	0.00361	CcSEcCtD
Agomelatine—Abdominal pain—Erlotinib—pancreatic cancer	0.00092	0.00358	CcSEcCtD
Agomelatine—Weight increased—Docetaxel—pancreatic cancer	0.000918	0.00357	CcSEcCtD
Agomelatine—Vision blurred—Fluorouracil—pancreatic cancer	0.000918	0.00357	CcSEcCtD
Agomelatine—Vertigo—Irinotecan—pancreatic cancer	0.000914	0.00355	CcSEcCtD
Agomelatine—Weight decreased—Docetaxel—pancreatic cancer	0.000913	0.00355	CcSEcCtD
Agomelatine—Insomnia—Sunitinib—pancreatic cancer	0.000911	0.00354	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Epirubicin—pancreatic cancer	0.000905	0.00352	CcSEcCtD
Agomelatine—Paraesthesia—Sunitinib—pancreatic cancer	0.000905	0.00352	CcSEcCtD
Agomelatine—Infestation NOS—Docetaxel—pancreatic cancer	0.0009	0.0035	CcSEcCtD
Agomelatine—Infestation—Docetaxel—pancreatic cancer	0.0009	0.0035	CcSEcCtD
Agomelatine—Dyspepsia—Sunitinib—pancreatic cancer	0.000887	0.00345	CcSEcCtD
Agomelatine—Jaundice—Docetaxel—pancreatic cancer	0.000877	0.00341	CcSEcCtD
Agomelatine—Eczema—Epirubicin—pancreatic cancer	0.000876	0.00341	CcSEcCtD
Agomelatine—Hepatic failure—Epirubicin—pancreatic cancer	0.000876	0.00341	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00087	0.00338	CcSEcCtD
Agomelatine—Fatigue—Sunitinib—pancreatic cancer	0.000869	0.00338	CcSEcCtD
Agomelatine—Constipation—Sunitinib—pancreatic cancer	0.000862	0.00335	CcSEcCtD
Agomelatine—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.000851	0.00331	CcSEcCtD
Agomelatine—Asthenia—Tamoxifen—pancreatic cancer	0.000844	0.00328	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—pancreatic cancer	0.000838	0.00326	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000838	0.00326	CcSEcCtD
Agomelatine—Asthenia—Erlotinib—pancreatic cancer	0.000835	0.00325	CcSEcCtD
Agomelatine—Pruritus—Tamoxifen—pancreatic cancer	0.000832	0.00323	CcSEcCtD
Agomelatine—Infection—Irinotecan—pancreatic cancer	0.000825	0.0032	CcSEcCtD
Agomelatine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000824	0.0032	CcSEcCtD
Agomelatine—Pruritus—Erlotinib—pancreatic cancer	0.000823	0.0032	CcSEcCtD
Agomelatine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000814	0.00316	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—pancreatic cancer	0.000811	0.00315	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—pancreatic cancer	0.000811	0.00315	CcSEcCtD
Agomelatine—Hepatitis—Docetaxel—pancreatic cancer	0.000808	0.00314	CcSEcCtD
Agomelatine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000805	0.00313	CcSEcCtD
Agomelatine—Infection—Gemcitabine—pancreatic cancer	0.000803	0.00312	CcSEcCtD
Agomelatine—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000802	0.00312	CcSEcCtD
Agomelatine—Abdominal pain—Sunitinib—pancreatic cancer	0.000796	0.0031	CcSEcCtD
Agomelatine—Diarrhoea—Erlotinib—pancreatic cancer	0.000796	0.0031	CcSEcCtD
Agomelatine—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000794	0.00308	CcSEcCtD
Agomelatine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000793	0.00308	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—pancreatic cancer	0.000792	0.0935	CrCbGaD
Agomelatine—Infection—Fluorouracil—pancreatic cancer	0.00079	0.00307	CcSEcCtD
Agomelatine—Skin disorder—Gemcitabine—pancreatic cancer	0.000785	0.00305	CcSEcCtD
Agomelatine—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000782	0.00304	CcSEcCtD
Agomelatine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00078	0.00303	CcSEcCtD
Agomelatine—Dizziness—Tamoxifen—pancreatic cancer	0.000778	0.00302	CcSEcCtD
Agomelatine—Migraine—Epirubicin—pancreatic cancer	0.000775	0.00301	CcSEcCtD
Agomelatine—Dizziness—Erlotinib—pancreatic cancer	0.00077	0.00299	CcSEcCtD
Agomelatine—Face oedema—Epirubicin—pancreatic cancer	0.00076	0.00295	CcSEcCtD
Agomelatine—Eye disorder—Docetaxel—pancreatic cancer	0.000755	0.00293	CcSEcCtD
Agomelatine—Insomnia—Irinotecan—pancreatic cancer	0.000751	0.00292	CcSEcCtD
Agomelatine—Vomiting—Tamoxifen—pancreatic cancer	0.000748	0.00291	CcSEcCtD
Agomelatine—Paraesthesia—Irinotecan—pancreatic cancer	0.000745	0.0029	CcSEcCtD
Agomelatine—Vomiting—Erlotinib—pancreatic cancer	0.00074	0.00288	CcSEcCtD
Agomelatine—Somnolence—Irinotecan—pancreatic cancer	0.000738	0.00287	CcSEcCtD
Agomelatine—Headache—Tamoxifen—pancreatic cancer	0.000737	0.00286	CcSEcCtD
Agomelatine—Insomnia—Gemcitabine—pancreatic cancer	0.000731	0.00284	CcSEcCtD
Agomelatine—Dyspepsia—Irinotecan—pancreatic cancer	0.000731	0.00284	CcSEcCtD
Agomelatine—Headache—Erlotinib—pancreatic cancer	0.000729	0.00283	CcSEcCtD
Agomelatine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000726	0.00282	CcSEcCtD
Agomelatine—Asthenia—Sunitinib—pancreatic cancer	0.000723	0.00281	CcSEcCtD
Agomelatine—Insomnia—Fluorouracil—pancreatic cancer	0.000719	0.00279	CcSEcCtD
Agomelatine—Somnolence—Gemcitabine—pancreatic cancer	0.000719	0.00279	CcSEcCtD
Agomelatine—Migraine—Doxorubicin—pancreatic cancer	0.000717	0.00279	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000717	0.00278	CcSEcCtD
Agomelatine—Fatigue—Irinotecan—pancreatic cancer	0.000716	0.00278	CcSEcCtD
Agomelatine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000714	0.00277	CcSEcCtD
Agomelatine—Pruritus—Sunitinib—pancreatic cancer	0.000713	0.00277	CcSEcCtD
Agomelatine—Constipation—Irinotecan—pancreatic cancer	0.00071	0.00276	CcSEcCtD
Agomelatine—Mental disorder—Docetaxel—pancreatic cancer	0.000707	0.00275	CcSEcCtD
Agomelatine—Somnolence—Fluorouracil—pancreatic cancer	0.000707	0.00275	CcSEcCtD
Agomelatine—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000704	0.00274	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—pancreatic cancer	0.000703	0.00273	CcSEcCtD
Agomelatine—Dyspepsia—Fluorouracil—pancreatic cancer	0.0007	0.00272	CcSEcCtD
Agomelatine—Nausea—Tamoxifen—pancreatic cancer	0.000699	0.00272	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000698	0.00271	CcSEcCtD
Agomelatine—Fatigue—Gemcitabine—pancreatic cancer	0.000697	0.00271	CcSEcCtD
Agomelatine—Constipation—Gemcitabine—pancreatic cancer	0.000691	0.00269	CcSEcCtD
Agomelatine—Nausea—Erlotinib—pancreatic cancer	0.000691	0.00269	CcSEcCtD
Agomelatine—Diarrhoea—Sunitinib—pancreatic cancer	0.000689	0.00268	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000686	0.00267	CcSEcCtD
Agomelatine—Influenza—Epirubicin—pancreatic cancer	0.00068	0.00264	CcSEcCtD
Agomelatine—Back pain—Docetaxel—pancreatic cancer	0.00068	0.00264	CcSEcCtD
Agomelatine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000679	0.00264	CcSEcCtD
Agomelatine—Dizziness—Sunitinib—pancreatic cancer	0.000666	0.00259	CcSEcCtD
Agomelatine—Abdominal pain—Irinotecan—pancreatic cancer	0.000656	0.00255	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000651	0.00253	CcSEcCtD
Agomelatine—Vomiting—Sunitinib—pancreatic cancer	0.000641	0.00249	CcSEcCtD
Agomelatine—Urticaria—Fluorouracil—pancreatic cancer	0.000631	0.00245	CcSEcCtD
Agomelatine—Headache—Sunitinib—pancreatic cancer	0.000631	0.00245	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—pancreatic cancer	0.00063	0.00245	CcSEcCtD
Agomelatine—Weight increased—Epirubicin—pancreatic cancer	0.000619	0.00241	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—pancreatic cancer	0.000616	0.00239	CcSEcCtD
Agomelatine—Infestation—Epirubicin—pancreatic cancer	0.000607	0.00236	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—pancreatic cancer	0.000607	0.00236	CcSEcCtD
Agomelatine—Nausea—Sunitinib—pancreatic cancer	0.000598	0.00233	CcSEcCtD
Agomelatine—Asthenia—Irinotecan—pancreatic cancer	0.000595	0.00231	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000594	0.00231	CcSEcCtD
Agomelatine—Jaundice—Epirubicin—pancreatic cancer	0.000591	0.0023	CcSEcCtD
Agomelatine—Dry mouth—Docetaxel—pancreatic cancer	0.000585	0.00227	CcSEcCtD
Agomelatine—Asthenia—Gemcitabine—pancreatic cancer	0.00058	0.00225	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000574	0.00223	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—pancreatic cancer	0.000573	0.00223	CcSEcCtD
Agomelatine—Pruritus—Gemcitabine—pancreatic cancer	0.000572	0.00222	CcSEcCtD
Agomelatine—Infection—Docetaxel—pancreatic cancer	0.00057	0.00222	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—pancreatic cancer	0.00057	0.00221	CcSEcCtD
Agomelatine—Diarrhoea—Irinotecan—pancreatic cancer	0.000568	0.00221	CcSEcCtD
Agomelatine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000563	0.00219	CcSEcCtD
Agomelatine—Pruritus—Fluorouracil—pancreatic cancer	0.000562	0.00219	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—pancreatic cancer	0.000561	0.00218	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—pancreatic cancer	0.000561	0.00218	CcSEcCtD
Agomelatine—Skin disorder—Docetaxel—pancreatic cancer	0.000557	0.00217	CcSEcCtD
Agomelatine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000553	0.00215	CcSEcCtD
Agomelatine—Dizziness—Irinotecan—pancreatic cancer	0.000549	0.00213	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—pancreatic cancer	0.000547	0.00213	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—pancreatic cancer	0.000545	0.00212	CcSEcCtD
Agomelatine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000544	0.00211	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000535	0.00208	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000531	0.00206	CcSEcCtD
Agomelatine—Vomiting—Irinotecan—pancreatic cancer	0.000528	0.00205	CcSEcCtD
Agomelatine—Dizziness—Fluorouracil—pancreatic cancer	0.000526	0.00204	CcSEcCtD
Agomelatine—Headache—Irinotecan—pancreatic cancer	0.00052	0.00202	CcSEcCtD
Agomelatine—Insomnia—Docetaxel—pancreatic cancer	0.000519	0.00202	CcSEcCtD
Agomelatine—Paraesthesia—Docetaxel—pancreatic cancer	0.000515	0.002	CcSEcCtD
Agomelatine—Vomiting—Gemcitabine—pancreatic cancer	0.000514	0.002	CcSEcCtD
Agomelatine—Somnolence—Docetaxel—pancreatic cancer	0.00051	0.00198	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—pancreatic cancer	0.000509	0.00198	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—pancreatic cancer	0.000508	0.00197	CcSEcCtD
Agomelatine—Headache—Gemcitabine—pancreatic cancer	0.000506	0.00197	CcSEcCtD
Agomelatine—Vomiting—Fluorouracil—pancreatic cancer	0.000505	0.00196	CcSEcCtD
Agomelatine—Dyspepsia—Docetaxel—pancreatic cancer	0.000505	0.00196	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—pancreatic cancer	0.000504	0.00196	CcSEcCtD
Agomelatine—Headache—Fluorouracil—pancreatic cancer	0.000498	0.00194	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000495	0.00193	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000495	0.00192	CcSEcCtD
Agomelatine—Fatigue—Docetaxel—pancreatic cancer	0.000495	0.00192	CcSEcCtD
Agomelatine—Nausea—Irinotecan—pancreatic cancer	0.000493	0.00192	CcSEcCtD
Agomelatine—Constipation—Docetaxel—pancreatic cancer	0.000491	0.00191	CcSEcCtD
Agomelatine—Nausea—Gemcitabine—pancreatic cancer	0.00048	0.00187	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—pancreatic cancer	0.000477	0.00185	CcSEcCtD
Agomelatine—Nausea—Fluorouracil—pancreatic cancer	0.000472	0.00184	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—pancreatic cancer	0.000471	0.00183	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—pancreatic cancer	0.00047	0.00183	CcSEcCtD
Agomelatine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000469	0.00182	CcSEcCtD
Agomelatine—Back pain—Epirubicin—pancreatic cancer	0.000459	0.00178	CcSEcCtD
Agomelatine—Abdominal pain—Docetaxel—pancreatic cancer	0.000454	0.00176	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—pancreatic cancer	0.000447	0.00174	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—pancreatic cancer	0.000442	0.00172	CcSEcCtD
Agomelatine—Agitation—Epirubicin—pancreatic cancer	0.000436	0.00169	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—pancreatic cancer	0.000426	0.00166	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—pancreatic cancer	0.000424	0.00165	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—pancreatic cancer	0.000413	0.00161	CcSEcCtD
Agomelatine—Asthenia—Docetaxel—pancreatic cancer	0.000412	0.0016	CcSEcCtD
Agomelatine—Pruritus—Docetaxel—pancreatic cancer	0.000406	0.00158	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—pancreatic cancer	0.000403	0.00157	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—pancreatic cancer	0.000402	0.00156	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000401	0.00156	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—pancreatic cancer	0.000395	0.00153	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—pancreatic cancer	0.000394	0.00153	CcSEcCtD
Agomelatine—Diarrhoea—Docetaxel—pancreatic cancer	0.000393	0.00153	CcSEcCtD
Agomelatine—Infection—Epirubicin—pancreatic cancer	0.000384	0.00149	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000379	0.00147	CcSEcCtD
Agomelatine—Dizziness—Docetaxel—pancreatic cancer	0.000379	0.00147	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—pancreatic cancer	0.000376	0.00146	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000374	0.00145	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—pancreatic cancer	0.000372	0.00145	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000371	0.00144	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—pancreatic cancer	0.000365	0.00142	CcSEcCtD
Agomelatine—Vomiting—Docetaxel—pancreatic cancer	0.000365	0.00142	CcSEcCtD
Agomelatine—Headache—Docetaxel—pancreatic cancer	0.000359	0.0014	CcSEcCtD
Agomelatine—Infection—Doxorubicin—pancreatic cancer	0.000356	0.00138	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000351	0.00136	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—pancreatic cancer	0.00035	0.00136	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—pancreatic cancer	0.000348	0.00135	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—pancreatic cancer	0.000347	0.00135	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000346	0.00135	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—pancreatic cancer	0.000344	0.00134	CcSEcCtD
Agomelatine—Nausea—Docetaxel—pancreatic cancer	0.000341	0.00132	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—pancreatic cancer	0.000341	0.00132	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000334	0.0013	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—pancreatic cancer	0.000334	0.0013	CcSEcCtD
Agomelatine—Constipation—Epirubicin—pancreatic cancer	0.000331	0.00129	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—pancreatic cancer	0.000324	0.00126	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000322	0.00125	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—pancreatic cancer	0.000318	0.00124	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000316	0.00123	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000315	0.00122	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000309	0.0012	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—pancreatic cancer	0.000309	0.0012	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—pancreatic cancer	0.000307	0.00119	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—pancreatic cancer	0.000306	0.00119	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—pancreatic cancer	0.000306	0.00119	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000293	0.00114	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—pancreatic cancer	0.000284	0.00111	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000283	0.0011	CcSEcCtD
Agomelatine—Asthenia—Epirubicin—pancreatic cancer	0.000278	0.00108	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—pancreatic cancer	0.000274	0.00106	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—pancreatic cancer	0.000265	0.00103	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—pancreatic cancer	0.000257	0.000998	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—pancreatic cancer	0.000256	0.000995	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—pancreatic cancer	0.000253	0.000985	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—pancreatic cancer	0.000246	0.000956	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000245	0.000952	CcSEcCtD
Agomelatine—Headache—Epirubicin—pancreatic cancer	0.000242	0.000942	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—pancreatic cancer	0.000237	0.00092	CcSEcCtD
Agomelatine—Nausea—Epirubicin—pancreatic cancer	0.00023	0.000893	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—pancreatic cancer	0.000228	0.000885	CcSEcCtD
Agomelatine—Headache—Doxorubicin—pancreatic cancer	0.000224	0.000872	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—pancreatic cancer	0.000213	0.000827	CcSEcCtD
Agomelatine—HTR2C—GPCR downstream signaling—GCG—pancreatic cancer	9.01e-05	0.000287	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	8.99e-05	0.000286	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCK—pancreatic cancer	8.87e-05	0.000283	CbGpPWpGaD
Agomelatine—HTR2C—G alpha (q) signalling events—PIK3CA—pancreatic cancer	8.77e-05	0.000279	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	8.71e-05	0.000278	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PIK3CA—pancreatic cancer	8.71e-05	0.000278	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—DTX4—pancreatic cancer	8.65e-05	0.000276	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GLI1—pancreatic cancer	8.65e-05	0.000276	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CNR2—pancreatic cancer	8.65e-05	0.000275	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GLP1R—pancreatic cancer	8.65e-05	0.000275	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—CXCL8—pancreatic cancer	8.64e-05	0.000275	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AGTR1—pancreatic cancer	8.6e-05	0.000274	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	8.54e-05	0.000272	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCKAR—pancreatic cancer	8.51e-05	0.000271	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CNR1—pancreatic cancer	8.47e-05	0.00027	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PIK3CB—pancreatic cancer	8.44e-05	0.000269	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PIK3CB—pancreatic cancer	8.44e-05	0.000269	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRP1—pancreatic cancer	8.42e-05	0.000268	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PPP2R5B—pancreatic cancer	8.42e-05	0.000268	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JAG2—pancreatic cancer	8.25e-05	0.000263	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—GCG—pancreatic cancer	8.18e-05	0.000261	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MEN1—pancreatic cancer	8.13e-05	0.000259	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CXCL8—pancreatic cancer	8.11e-05	0.000258	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CXCL8—pancreatic cancer	8.11e-05	0.000258	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HEY2—pancreatic cancer	8.1e-05	0.000258	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HRAS—pancreatic cancer	8.06e-05	0.000257	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—HRAS—pancreatic cancer	8.06e-05	0.000257	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GAST—pancreatic cancer	7.91e-05	0.000252	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	7.84e-05	0.00025	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—AKT1—pancreatic cancer	7.84e-05	0.00025	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—AKT1—pancreatic cancer	7.84e-05	0.00025	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AGTR1—pancreatic cancer	7.81e-05	0.000249	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CASP3—pancreatic cancer	7.77e-05	0.000247	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CASP3—pancreatic cancer	7.77e-05	0.000247	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SHH—pancreatic cancer	7.75e-05	0.000247	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOTCH4—pancreatic cancer	7.71e-05	0.000245	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IAPP—pancreatic cancer	7.66e-05	0.000244	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCND1—pancreatic cancer	7.56e-05	0.000241	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCND1—pancreatic cancer	7.56e-05	0.000241	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SCT—pancreatic cancer	7.5e-05	0.000239	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HEY1—pancreatic cancer	7.5e-05	0.000239	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CTNNB1—pancreatic cancer	7.49e-05	0.000238	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CTNNB1—pancreatic cancer	7.49e-05	0.000238	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTHLH—pancreatic cancer	7.35e-05	0.000234	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTCH1—pancreatic cancer	7.35e-05	0.000234	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MMP9—pancreatic cancer	7.34e-05	0.000234	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MMP9—pancreatic cancer	7.34e-05	0.000234	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTEN—pancreatic cancer	7.3e-05	0.000232	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTEN—pancreatic cancer	7.3e-05	0.000232	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	7.26e-05	0.000231	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCK—pancreatic cancer	7.16e-05	0.000228	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—AKT1—pancreatic cancer	7.12e-05	0.000227	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—AKT1—pancreatic cancer	7.12e-05	0.000227	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CNR2—pancreatic cancer	6.98e-05	0.000222	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GLP1R—pancreatic cancer	6.98e-05	0.000222	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CXCL8—pancreatic cancer	6.97e-05	0.000222	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PRSS1—pancreatic cancer	6.97e-05	0.000222	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCKAR—pancreatic cancer	6.86e-05	0.000219	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SRC—pancreatic cancer	6.77e-05	0.000216	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SRC—pancreatic cancer	6.77e-05	0.000216	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SST—pancreatic cancer	6.72e-05	0.000214	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JAG2—pancreatic cancer	6.65e-05	0.000212	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CG—pancreatic cancer	6.63e-05	0.000211	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VEGFA—pancreatic cancer	6.59e-05	0.00021	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VEGFA—pancreatic cancer	6.59e-05	0.00021	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JAG1—pancreatic cancer	6.58e-05	0.00021	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MEN1—pancreatic cancer	6.56e-05	0.000209	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOTCH3—pancreatic cancer	6.55e-05	0.000209	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—STAT3—pancreatic cancer	6.53e-05	0.000208	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—STAT3—pancreatic cancer	6.53e-05	0.000208	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NRAS—pancreatic cancer	6.51e-05	0.000207	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NRAS—pancreatic cancer	6.51e-05	0.000207	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SHH—pancreatic cancer	6.26e-05	0.000199	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOTCH4—pancreatic cancer	6.22e-05	0.000198	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CNR1—pancreatic cancer	6.21e-05	0.000198	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IAPP—pancreatic cancer	6.18e-05	0.000197	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MYC—pancreatic cancer	6.06e-05	0.000193	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MYC—pancreatic cancer	6.06e-05	0.000193	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TGFB1—pancreatic cancer	6.05e-05	0.000193	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TGFB1—pancreatic cancer	6.05e-05	0.000193	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ARG2—pancreatic cancer	6.04e-05	0.000192	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CG—pancreatic cancer	6.02e-05	0.000192	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GCG—pancreatic cancer	5.99e-05	0.000191	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PRSS1—pancreatic cancer	5.96e-05	0.00019	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—EGFR—pancreatic cancer	5.93e-05	0.000189	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—EGFR—pancreatic cancer	5.93e-05	0.000189	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTHLH—pancreatic cancer	5.93e-05	0.000189	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTCH1—pancreatic cancer	5.93e-05	0.000189	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CD—pancreatic cancer	5.83e-05	0.000186	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AGTR1—pancreatic cancer	5.72e-05	0.000182	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STK11—pancreatic cancer	5.63e-05	0.000179	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KRAS—pancreatic cancer	5.6e-05	0.000178	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KRAS—pancreatic cancer	5.6e-05	0.000178	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SST—pancreatic cancer	5.42e-05	0.000173	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.35e-05	0.00017	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JAG1—pancreatic cancer	5.31e-05	0.000169	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CD—pancreatic cancer	5.29e-05	0.000169	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOTCH3—pancreatic cancer	5.29e-05	0.000168	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMP—pancreatic cancer	5.28e-05	0.000168	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ARG2—pancreatic cancer	5.16e-05	0.000164	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PIK3CA—pancreatic cancer	5.15e-05	0.000164	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PIK3CA—pancreatic cancer	5.15e-05	0.000164	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.08e-05	0.000162	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CNR1—pancreatic cancer	5.01e-05	0.000159	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—pancreatic cancer	4.98e-05	0.000159	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—pancreatic cancer	4.98e-05	0.000159	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SMAD4—pancreatic cancer	4.94e-05	0.000157	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—CXCL8—pancreatic cancer	4.88e-05	0.000156	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CG—pancreatic cancer	4.86e-05	0.000155	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GCG—pancreatic cancer	4.83e-05	0.000154	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HES1—pancreatic cancer	4.82e-05	0.000153	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—pancreatic cancer	4.76e-05	0.000152	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—pancreatic cancer	4.76e-05	0.000152	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CD—pancreatic cancer	4.7e-05	0.00015	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CB—pancreatic cancer	4.61e-05	0.000147	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AGTR1—pancreatic cancer	4.61e-05	0.000147	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STK11—pancreatic cancer	4.55e-05	0.000145	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMP—pancreatic cancer	4.51e-05	0.000144	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CXCL8—pancreatic cancer	4.43e-05	0.000141	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.36e-05	0.000139	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CD—pancreatic cancer	4.27e-05	0.000136	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GLP1R—pancreatic cancer	4.26e-05	0.000136	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—pancreatic cancer	4.22e-05	0.000134	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—pancreatic cancer	4.21e-05	0.000134	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—pancreatic cancer	4.21e-05	0.000134	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—DPYD—pancreatic cancer	4.19e-05	0.000133	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.1e-05	0.000131	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HIF1A—pancreatic cancer	4.04e-05	0.000129	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TSC2—pancreatic cancer	4.03e-05	0.000128	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SMAD4—pancreatic cancer	3.98e-05	0.000127	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	3.97e-05	0.000127	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—APOE—pancreatic cancer	3.94e-05	0.000126	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CXCL8—pancreatic cancer	3.94e-05	0.000125	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.93e-05	0.000125	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HES1—pancreatic cancer	3.89e-05	0.000124	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KDR—pancreatic cancer	3.86e-05	0.000123	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.8e-05	0.000121	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.72e-05	0.000119	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CB—pancreatic cancer	3.72e-05	0.000119	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NFKBIA—pancreatic cancer	3.67e-05	0.000117	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GLP1R—pancreatic cancer	3.64e-05	0.000116	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOTCH1—pancreatic cancer	3.64e-05	0.000116	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—DPYD—pancreatic cancer	3.58e-05	0.000114	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CXCL8—pancreatic cancer	3.58e-05	0.000114	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CG—pancreatic cancer	3.56e-05	0.000113	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—NRAS—pancreatic cancer	3.56e-05	0.000113	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGF—pancreatic cancer	3.52e-05	0.000112	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.46e-05	0.00011	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—pancreatic cancer	3.41e-05	0.000109	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	3.4e-05	0.000108	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.36e-05	0.000107	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HIF1A—pancreatic cancer	3.26e-05	0.000104	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TSC2—pancreatic cancer	3.25e-05	0.000104	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.24e-05	0.000103	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—EGFR—pancreatic cancer	3.24e-05	0.000103	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—APOE—pancreatic cancer	3.18e-05	0.000101	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CD—pancreatic cancer	3.13e-05	9.96e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KDR—pancreatic cancer	3.12e-05	9.92e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.1e-05	9.87e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CD44—pancreatic cancer	3.08e-05	9.8e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—pancreatic cancer	3.06e-05	9.75e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.01e-05	9.6e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.99e-05	9.51e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NFKBIA—pancreatic cancer	2.96e-05	9.44e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.95e-05	9.41e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GCG—pancreatic cancer	2.95e-05	9.4e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	2.93e-05	9.35e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	2.87e-05	9.14e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	2.87e-05	9.14e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGF—pancreatic cancer	2.84e-05	9.04e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—pancreatic cancer	2.81e-05	8.96e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—STK11—pancreatic cancer	2.77e-05	8.84e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CB—pancreatic cancer	2.73e-05	8.68e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CD44—pancreatic cancer	2.63e-05	8.38e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CXCL8—pancreatic cancer	2.62e-05	8.34e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	2.61e-05	8.33e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.6e-05	8.3e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—pancreatic cancer	2.6e-05	8.29e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.58e-05	8.2e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.55e-05	8.13e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	2.53e-05	8.06e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	2.52e-05	8.04e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GCG—pancreatic cancer	2.52e-05	8.03e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	2.51e-05	7.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.5e-05	7.96e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	2.47e-05	7.87e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	2.44e-05	7.77e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	2.42e-05	7.7e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMS—pancreatic cancer	2.39e-05	7.6e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—STK11—pancreatic cancer	2.37e-05	7.55e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	2.37e-05	7.55e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	2.36e-05	7.5e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	2.3e-05	7.32e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	2.27e-05	7.23e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.23e-05	7.09e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	2.2e-05	7e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SRC—pancreatic cancer	2.18e-05	6.96e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	2.13e-05	6.78e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	2.11e-05	6.73e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	2.11e-05	6.71e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	2.1e-05	6.69e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	2.1e-05	6.69e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	2.04e-05	6.5e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMS—pancreatic cancer	2.04e-05	6.5e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	2.02e-05	6.44e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	1.97e-05	6.27e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—pancreatic cancer	1.96e-05	6.23e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	1.95e-05	6.22e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.95e-05	6.21e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—APOE—pancreatic cancer	1.94e-05	6.18e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	1.91e-05	6.1e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	1.91e-05	6.09e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	1.9e-05	6.05e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.85e-05	5.91e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.84e-05	5.85e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	1.81e-05	5.76e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	1.76e-05	5.61e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	1.75e-05	5.58e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	1.72e-05	5.47e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	1.7e-05	5.41e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	1.7e-05	5.4e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARG—pancreatic cancer	1.69e-05	5.39e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.66e-05	5.29e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—APOE—pancreatic cancer	1.66e-05	5.28e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—pancreatic cancer	1.61e-05	5.12e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.58e-05	5.03e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.58e-05	5.02e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.57e-05	5e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.54e-05	4.92e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	1.54e-05	4.9e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	1.54e-05	4.9e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.5e-05	4.77e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.46e-05	4.65e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.44e-05	4.6e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	1.36e-05	4.32e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.34e-05	4.28e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.34e-05	4.27e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.33e-05	4.24e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.32e-05	4.19e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	1.3e-05	4.13e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	1.24e-05	3.95e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.16e-05	3.69e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.15e-05	3.65e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.14e-05	3.62e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	1.1e-05	3.49e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—pancreatic cancer	9.91e-06	3.16e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	8.18e-06	2.61e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	6.99e-06	2.23e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—pancreatic cancer	6.68e-06	2.13e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—pancreatic cancer	5.71e-06	1.82e-05	CbGpPWpGaD
